Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
07. April 2021 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
25. März 2021 16:05 ET
|
Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
18. März 2021 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update
11. November 2020 16:05 ET
|
Trevi Therapeutics
PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject...
Trevi Therapeutics to Present at Stifel Healthcare Conference
10. November 2020 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
17. Juni 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
08. April 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
LIFESPRK ANNOUNCES $16.1 MILLION SERIES A PREFERRED INVESTMENT LED BY VIRGO INVESTMENT GROUP
07. April 2020 14:10 ET
|
Lifesprk
Minneapolis, MN, April 07, 2020 (GLOBE NEWSWIRE) -- Lifesprk, LLC (“Lifesprk”), a leader in whole person services for seniors, announces $16.1 million Series A Preferred stock investment led by...